Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Doubleblind,Placebo Controlled, Parallel Group, Pilot Study of 40:1 Ratio of Formulated GW42003 :GW42004 in the Treatment of Iatrogenic Weight Gain and Dyslipidaemia Associated With Olanzapine Treatment in Subjects With Functional Psychosis

NCT01491490 is registered in ClinicalTrials.gov with GW Research Ltd as lead sponsor.

NCT NCT01491490
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01491490 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Doubleblind,Placebo Controlled, Parallel Group, Pilot Study of 40:1 Ratio of Formulated GW42003 :GW42004 in the Treatment of Iatrogenic Weight Gain and Dyslipidaemia Associated With Olanzapine Treatment in Subjects With Functional Psychosis
Lead sponsor
GW Research Ltd
Phase
Phase 2
Overall status
Terminated
Start date
October 31, 2011
Completion date
October 31, 2012
Enrollment
2 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia